,i  #aae? ,,congress  #b;d ,session  ,h4
 ,r4 #ehfg  ,,9 ,,! ,,h\se ,,(          
,,repres5tatives  ,may #ag1 #bjah,mr4   
,doggett 7= himself & ,ms4 ,p+ree7      
introduc$ ! foll[+ bill2 :i* 0 ref]r$ to
 ! ,committee on ,en]gy & ,comm]ce  ,a  
,,bill  ,to au?orize a jo9t action plan 
& report on drug wa/e4  #a4 ,%ort title 
,?is ,act may be cit$ z ! ,r$uc+ ,drug  
,wa/e ,act ( #bjah4  #b4 ,f9d+s         
,congress f9ds z foll[s3  7#a7 ,on ,may 
#bc1 #bjag1 ! ,dep>tm5t ( ,heal? &      
,human ,s]vices1 act+ ?r\gh ! ,(fice ( !
 ,inspector ,g5]al 9 a lett] to ,s5ators
 ,klobu*>1 ,durb91 & ,%ahe51 f\nd t     
diff]5t vial sizes 9 addition to ^?     
curr5tly approv$ & m>ket$ 9 ! ,unit$    
,/ates c\ld sometimes significantly     
r$uce ! am\nt ( drug disc>ds1 or wa/e1 f
 s+le-use vials4  7#b7 ,! ,(fice (      
,inspector ,g5]al analyz$ #bj s+le-use  
vial drugs ) ! highe/ am\nts (          
id5tifiable reimbursem5t = disc>d$ drugs
 dur+ #bjac & #bjad & f\nd t ! ,m$ic>e  
"p ,b program paid #aa1fjj1jjj1jjj = ^! 

drugs1 #b1ajj1jjj1jjj ( :i* 0 = drugs   
bill$ 9 increm5ts ( o!r-?an-full vials1 
& #aie1jjj1jjj1 or ne>ly #aj p]c5t1 ( ! 
#b1ajj1jjj1jjj bill$ 9 increm5ts (      
o!r-?an-full vials 0 reimburs$ = disc>d$
 drugs4  7#c7 ,dur+ ! ,food & ,drug     
,adm9i/ration's review process = a      
drug's safety & efficacy be=e a drug is 
approv$ = m>ket+ 9 ! ,unit$ ,/ates1 !   
,food & ,drug ,adm9i/ration reviews !   
manufactur]'s propos$ vial size4  7#d7  
,z ( ,janu>y #a1 #bjag1 ! ,c5t]s =      
,m$ic>e  ,m$icaid ,s]vices requires all 
physicians1 hospitals1 & o!r provid]s   
submitt+ claims to ,m$ic>e to sep>ately 
id5tify ! disc>d$ am\nt ( a drug f a    
s+le-use vial 7! ,,jw modifi]7 on its   
claim = reimbursem5t by ,m$ic>e4 ,! new 
requirem5t does n *ange ! am\nt !       
provid]s are reimburs$ = s+le-use drugs4
  #c4 ,jo9t action plan & report on drug
 wa/e  7a7 ,jo9t action plan ,!         
,commission] ( ,food & ,drugs1 9        
coord9ation ) ! ,adm9i/rator ( ! ,c5t]s 
= ,m$ic>e  ,m$icaid ,s]vices1 %all      

develop a jo9t action plan1 9           
consultation ) heal? c>e provid]s &     
pati5t advocates 7includ+ relevant      
,f$]al advisory committees7 t--  7#a7   
utilizes data f ,m$ic>e claims on h[ mu*
 ( a s+le-use drug 0 n adm9i/]$1 comp>+ 
s+le-use vial sizes 9 o!r c\ntries1 &   
?r\gh analysis dur+ ! drug approval     
process ( alt]native vial size safety & 
efficacy1 to r$uce drug wa/e & bett]    
manage co/s2 &  7#b7 includes           
quantifiable metrics & specific         
timel9es4  7b7 ,report ,n lat] ?an #a   
ye> aft] ! date ( enactm5t ( ?is ,act1 !
 ,commission] ( ,food & ,drugs1 9       
coord9ation ) ! ,adm9i/rator ( ! ,c5t]s 
= ,m$ic>e  ,m$icaid ,s]vices1 %all      
submit to ,congress ! jo9t action plan  
describ$ 9 subsection 7a7 & a report    
conta9+ recomm5dations = any legislative
 action ne$$ to r$uce drug wa/e & bett] 
manage co/s4